Horizon Therapeutics Gets FDA Approval for Eye Drug
After market close on Tuesday, Irish drug company Horizon Therapeutics (NASDAQ: HZNP) received a nice surprise from the Food and Drug Administration (FDA). The company's drug Tepezza was approved earlier than expected. This is the first therapy that will hit the market for thyroid eye disease (TED), a rare condition caused by an autoimmune disorder.
TED, which is sometimes referred to as Graves' Eye Disease, can range from mild to severe. It's marked by an inflammation in the eye muscles, eyelids, tear glands and fatty tissues of the eye, which causes them to become red, swollen, and uncomfortable. Approximately one million Americans are diagnosed with the condition each year, with women five times more likely to suffer from it than men.
Image source: Getty Images
Source Fool.com
